Product1 distinct publisher3 min readUpdated
Enhanced Group lost nearly $62 million in Q2 against $17.7 million of revenue, most of it sponsorship money tied to the event. The telehealth business it was built on is barely visible.
The Product Desk · Product desk

Compiled by The Product DeskSomething wrong?How this is made
Enhanced Group, the telehealth company that staged the Enhanced Games in Las Vegas in May, reported a net loss of nearly $62 million for the second quarter, with much of it attributed to hosting the event [s1c1]. Against $17.7 million in revenue, most of which came from sponsorships tied to the games rather than the telehealth business the company was built on, that is a usable number for what it costs to buy sporting legitimacy [s1c3].
Work the arithmetic. Revenue of $17.7 million and a loss of nearly $62 million imply roughly $79.7 million of costs in the quarter [s1d1], or about $4.50 spent for every dollar collected [s1d2]. The company went public earlier this year at a $1.2 billion valuation, having been founded in 2023 [s1c6], which means a single quarter's loss consumed something on the order of 5 percent of the IPO valuation [s1d3].
The revenue mix is the part product people should sit with. Enhanced sells personalized health treatments through a digital telehealth platform, including FDA-approved peptides, testosterone injections and GLP-1s [s1c6]. But the money in Q2 came from sponsors buying proximity to a spectacle, and TechCrunch reports that scant information is available about how the core business is actually performing [s1c4]. That is a marketing line item reported as revenue, and it obscures the only question that matters: whether the telehealth funnel converts without an event attached.
The event itself did not deliver the demo. The games were billed by their creators as something that would fundamentally transform organized sports [s1c16], yet only one world record fell, and it came in swimming, where records break often [s1c5]. The competition was backed by investors including Peter Thiel and staffed by veterans of the crypto, AI and biotech industries, and was widely derided as the "steroid Olympics" [s1c7].
The pivot is already in the filing. The report casts doubt on earlier executive claims that the games would be annual, noting the company would either need far more revenue or tolerance for losing tens of millions a year [s1c8]. It also promotes Enhanced Breakers, a new online series the company says "operates at a fraction of the cost of a full Games event" while keeping "athletes competing, audiences engaged, sponsors interested, and performance medicine in front of the world year-round" [s1c9]. Translated: keep the marketing surface, drop the stadium.
Meanwhile the category is moving without them. TechCrunch reports the peptide business is booming, helped by a Trump administration FDA decision reclassifying substances long in a legal gray area, though an additional review is still required before sales open up [s1c10]. The FDA's parent agency, HHS, is overseen by Robert F. Kennedy Jr., whose health views have been characterized as dangerous by professionals inside and outside government [s1c11]. Silicon Valley startups such as Superpower and Noho Labs are growing faster than state regulators can write rules [s1c12].
Watch Q3, the first quarter with no games in it. That report is the first clean read on telehealth revenue, and on whether sponsors follow Enhanced onto the internet.
Follow any of these and your For You feed starts watching them — no settings page required.
Ranked by verification strength, evidence, and original report placement.
The peptide business is booming, helped by a recent decision from the Trump administration's FDA to reclassify a number of substances that had long resided in a legally gray area; an additional review process still needs to take place before sales open up.
Enhanced Group, the company that put on the Enhanced Games, posted a second-quarter net loss of nearly $62 million, with much of that loss coming from hosting the games.
The Enhanced Games, a competition that lets athletes compete while using performance-enhancing drugs typically banned in professional sports, was held in Las Vegas in May.
The company's Q2 earnings report says it brought in $17.7 million in the quarter, but most of that money came from sponsorships tied to the games, not the telehealth business on which the company was built.
Scant information is available about how the company's core telehealth business is doing.
At the games, only one world record fell, and it came in swimming, a sport where records are broken often.
Evidence-backed comparisons of source perspectives and observed adoption signals. Read the methodology
Which Builder, Operator, and Investor concerns the observed source mix emphasized—not a truth score.
Evidence, demonstrated adoption, hype gap, incentives, and confidence are assessed independently, each on its own current evidence. How these are measured.
Company financial disclosure, single outlet
The core numbers — $17.7 million revenue, nearly $62 million net loss, $1.2 billion IPO valuation — come from the company's own Q2 earnings report as read by one publisher, which is strong primary sourcing for the financial spine of the story. Evidence weakens sharply beyond that: no cash, opex or segment breakdown, no telehealth metrics, no company response, and the sector-growth and regulatory-lag assertions carry no figures or named rules.
One event staged, revenue concentrated, core platform unmeasured
There is real-world execution to point at: a full live competition staged in Las Vegas, sponsorship dollars actually booked, and a follow-on online series launched. But adoption of the thing the company is built on is invisible — no telehealth patient, subscription or repeat-purchase data — and the games' own draw is characterized as anticlimactic with a single world record, so demonstrated traction is narrow and event-dependent.
Transformation pitch versus one record and a 4.5x cost ratio
Creators billed the games as fundamentally transforming organized sport and executives suggested an annual cadence; the measured outcome was one world record in a record-prone sport, roughly $4.50 of cost per dollar of revenue, a quarterly loss equal to about 5 percent of the IPO valuation, and a pivot to a cheaper online format. The gap is clearly positive, though not maximal: the FDA reclassification is a genuine, if incomplete, tailwind and the company did execute the event it promised.
Post-IPO spectacle marketing meets deregulatory tailwind
Incentives are strongly aligned toward promotion on multiple sides: a newly public $1.2 billion company using a televised spectacle and sponsorship deals as marketing for a treatment-selling platform, high-profile backing including Peter Thiel, an explicit company statement that Breakers keeps 'sponsors interested' and 'performance medicine in front of the world year-round', and a federal regulatory posture favorable to deregulating gray-area substances under contested HHS leadership. The publisher's own incentive — an on-site reporter revisiting an event it covered — also colors the framing.
Solid on the numbers, thin everywhere else
Confidence is moderate: the financial claims rest on a company disclosure and simple arithmetic, which is durable, but the cluster has one publisher, no corroboration, no company response, and no data on the telehealth business, peptide market size or state-level regulation. Judgments about the pivot and the sector's trajectory are therefore interpretive.
science
An FDA panel wants unapproved peptides sold by prescription. That is deregulation, not wellness.1 distinct publisher
invest
Tiny corp wants Etched's numbers. Jane Street led $700M at $21B without publishing any1 distinct publisher
science
HIPAA Covers Less Than You Think, And "Anonymized" Is Not A Legal Shield1 distinct publisher
science
97% of the record menthol-ban comments were form letters, Rutgers audit of all 246,808 finds1 distinct publisher
Distinct publishers with included, body-backed reporting in this cluster.